Vicarious Surgical

The NYSE initiated a delisting of Vicarious Surgical’s common stock after the 30‑trading-day average global market capitalization of $13.67 million fell below the $15 million minimum. NYSE trading was suspended after the close; the company can appeal within ten business days. Vicarious Surgical has been approved to trade on the OTCQB under the ticker RBOT, with trading set to begin the same day. The stock has fallen roughly 81% over the past year and is trading at about $1.92. » More on de.investing.com

Vicarious Surgical sold 1,150,000 Class A shares (including pre-funded warrants) at an effective price of $5.10 per share, generating gross proceeds of approximately $5.9 million. Each share includes warrants to purchase two additional shares; the Series A and B warrants run for five years, and Series B can be repurchased for $0.01 upon achievement of certain price/volume milestones. The proceeds are intended for general corporate purposes, working capital and R&D, while the company—despite a high current ratio—has been rapidly depleting cash reserves and posted a negative EBITDA of $60.17 million over the last twelve months. Vicarious Surgical also reported cost reductions in Q2, a price target cut by Piper Sandler, and the appointment of Joseph Doherty as board chair; clinical trials have been postponed until system maturity. » More on de.investing.com

Vicarious Surgical has appointed Joseph Doherty as chairman of the Board of Directors; Doherty has served on the board since June 2025 and brings leadership experience from companies such as Johnson & Johnson and Olympus Surgical Technologies. The surgical robotics specialist, according to InvestingPro, shows a “fair” financial valuation despite market problems, has more cash than debt but a high cash burn rate. For Q2/2025 Vicarious reported a significant reduction in operating expenses and an adjusted EPS of -$2.23 (better than expected); at the same time clinical trials were postponed and Piper Sandler cut its price target to $7.00 with a “neutral” rating. Analyst targets range from $7 to $13, the share price is $5.49 and the stock could be undervalued according to the analysis. » More on de.investing.com